EGFR and hepatocellular carcinoma: Erlotinib, a TKI that primarily targets the epidermal growth factor receptor; a meta-analysis showed that erlotinib in combination with the anti-angiogenesis-targeting agent, bevacizumab, is effective for the second-line therapy of advanced HCC [61].